ClinicalTrials.gg
RecruitingNCT06558604GLOASISUpdated Jul 10, 2026

Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

A Phase 2 interventional study of Obinutuzumab and Glofitamab in Lymphoma, Mantle-Cell, sponsored by The Lymphoma Academic Research Organisation. Recruiting at 16 sites in 2 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by The Lymphoma Academic Research Organisation · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing glofitamab in Lymphoma, Mantle-Cell — 11 open to participants now, 12 under way, none of them phase 3. glofitamab · Lymphoma, Mantle-Cell.

Planned enrollment
Largest of 13
100 · median 40
Started
2025
with 2 others
Phase 2
9 of 13
8 open now
Primary completion
2028-05
later than 8 of 11 live
Registered
8th of 13
by date
Lead sponsor
2 of 13
The Lymphoma Academic Research Organisation

Among the 13 studies testing glofitamab in Lymphoma, Mantle-Cell, this one has the largest planned enrollment, is one of 3 that started in 2025, is one of 9 in phase 2, reaches primary completion later than 8 of the 11 other live ones, and was the 8th registered.

Lymphoma, Mantle-Cell

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

11 of the 13 studies testing glofitamab in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About glofitamab

glofitamab: first FDA approval 2023 (COLUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing glofitamab in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

This open-label, multicenter, three cohorts, phase II study is designed to assess a combination of Zanubrutinib/Venetoclax/Glofitamab or Venetoclax/Glofitamab in high-risk subjects with either first line or R/R Mantle Cell Lymphoma (MCL).

Three independent cohorts will be run:

  • Cohort A will include subjects with a primary refractory or progressive disease within 24 months from initiation of first line treatment (POD 24).
  • Cohort B will be open for subjects with R/R MCL and refractory or progressive to a BTK inhibitor given previously (>24 months if first line).
  • Cohort C will only enrol newly diagnosed and untreated MCL subjects with very high-risk features.
Read the detailed description

Cohort A : 40 subjects will be included and treated Cohort B : 36 subjects will be included and treated Cohort C : 24 subjects will be included and treated

Subjects in cohorts A and C will receive during induction phase 12 cycles of Zanubrutinib/Venetoclax/Glofitamab and during maintenance phase 23 cycles of Zanubrutinib/Venetoclax

Subjects in cohort B will receive during induction phase 12 cycles of Venetoclax/Glofitamab and during maintenance phase 23 cycles of Venetoclax

03

Conditions studied

  • Lymphoma, Mantle-Cell

Keywords

  • POD24
  • BTKI failure
  • High risk
  • 18 to 79 years
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

In cohort A, participant must meet the following inclusion criteria:

  1. Participant must be primary or in progression within 24 months from initiation of treatment (POD24 defined as time between D1C1 of the first treatment line and ICF signature)) (including an anti-CD20 combined with chemotherapy). Participant previously exposed to BTK inhibitor at first line is eligible. Participant in failure of CAR-T cell first line is eligible.
  2. Primary refractory participants (i.e., with a progressive disease) to the BTKi and Venetoclax combination will not be eligible.

    In cohort B, participant must meet the following inclusion criterion:

  3. Participant must be R/R MCL and refractory or progressive to a BTK inhibitor given in a previous line of treatment (the number of treatment lines is not limited). If first progression, time from diagnosis (defined as D1C1 of the first treatment line) to inclusion (defined as the date of ICF signature) must be superior to 24 months.
  4. Participant previously exposed to Bcl-2 therapy and/or relapsing post CAR-T cell therapy is eligible, except if they presented a progressive disease under BTKi and Venetoclax combination.

    In cohort C, participant must meet the following inclusion criteria:

  5. Participant not previously treated for mantle cell lymphoma.
  6. Participant at high risk of relapse presenting at least two of the following risk factors:

    1. TP53 mutation, del17p, or p53 expression (IHC) > 50%,
    2. blastoïd variant,
    3. complex karyotype defined as 3 or more abnormalities additional to t(11;14),
    4. c-myc rearrangement (FISH),
    5. Ki67≥30%,
    6. high MIPI score, (or MIPI simplified)
    7. high MIPI-combined score ((ie high MIPI score + Ki67≥30%): this criterion alone is sufficient.

    Participant must meet all of the following additional criteria to be enrolled in the study for cohort A, B and C:

  7. Participant is ≥ 18 years and \< 80 years of age at the time of signing the form (ICF).
  8. Participant understood and voluntarily signed and dated an informed consent prior to any study-specific assessments/procedures being conducted.
  9. Participant with proven mantle cell lymphoma (latest WHO classification). The diagnosis has to be confirmed by phenotypic expression of CD5, CD20 and cyclin D1 or the t(11;14) translocation. Diagnostic tissue should be available for central pathology review and ancillary molecular studies.
  10. Bi-dimensionally defined by at least one single node or tumor lesion ≥ 1.5 cm assessed by CT scan, or one bi-dimensionally measurable (≥1 cm) extranodal lesion, as measured on CT scan, and/or clinical examination.
  11. Stage II-IV disease,
  12. performance status of 0, 1, 2.
  13. of more than 3 months.
  14. Adequate renal function as demonstrated by a > 30 mL/min; calculated by the Cockcroft Gault formula or formula.
  15. Adequate hepatic function per local laboratory reference range as follow (unless if due to lymphoma involvement):

    1. (AST) and alanine transaminase (ALT) ≤ 2.5x (ULN)
    2. \< 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin. in which case total bilirubin should be \< 3 x ULN).
  16. Women of (WOCBP) (refer to section 14.7 for more details) must have negative results for highly effective urine/serum pregnancy test 10-14 days prior to Day 1 of Cycle 1 and within 24 hours prior to day 1 Cycle 1 prior to initiating study treatment and agree to abstain from becoming pregnant or breastfeeding during study participation and until at least 18 months after C1 with Obinutuzumab, or 3 months after the final dose of tocilizumab (if applicable), or 2 months after the final dose of Glofitamab, or or 1 month after the final dose of Zanubrutinib (if applicable), or 30 days after the final dose of Venetoclax, whichever is longer. WOCBP agree to remain abstinent (from heterosexual intercourse) or use two methods of , and to refrain from donating eggs, during the treatment period and for at least 18 months after the final dose of Obinutuzumab, 3 months after the final dose of tocilizumab (if applicable), 2 months after the final dose of Glofitamab, 1 month after the final dose of Zanubrutinib (if applicable), and 30 days after the final dose of Venetoclax (refer to section 14.6).
  17. Men of (refer to section 14.6 for more details) agree to remain abstinent (from heterosexual intercourse) or use effective methods of birth control with a non-pregnant female partner of childbearing potential or a pregnant female partner and to refrain from donating sperm, during the treatment period and for at least 3 months after the final dose of Obinutuzumab, 2 months after the final dose of Glofitamab, 2 months after the final dose tocilizumab (if applicable), 30 days after the final dose of Venetoclax, 1 week after the final dose of Zanubrutinib (if applicable).
  18. Adequate bone marrow function as defined by:

    1. (ANC) ≥ 1000/mm3, except for participants with bone marrow involvement in which ANC must be ≥ 500/mm3.
    2. ≥ 75,000/mm3, except for participants with bone marrow involvement in which the platelet count must be ≥ 50,000/mm3.
  19. Participant covered by any social security system (France).
  20. Participant who understands and speaks one of the country official languages unless local regulation authorizes independent translators.
  21. Participant with a SARS-COV2 vaccination status in line with local National guidelines/recommendations (COSV, ANRS MIE).
  22. Participant must be willing and able to comply with protocol-mandated hospitalization upon administration of the first two doses of Glofitamab. Participant must also be willing to comply with all study-related procedures.
  23. Adverse events from prior anti-cancer therapy must have resolved to Grade ≤ 1 (hematological toxicities excepted)

Participant who meets any of the following criteria will be excluded from enrollment in the study for cohort A, B and C:

  1. Proven or previously known CD20 negative status on FFPE IHC at time of MCL relapse or diagnosis.
  2. For Participant in Cohort A and B: previously refractory to treatment by BTK inhibitor and Bcl-2 therapy combination.
  3. Any prior therapy with a bispecific antibody targeting CD3 and CD20.
  4. Current or past history of central nervous system or meningeal involvement by lymphoma.
  5. Use of any standard or experimental anti-cancer drug therapy including biological agents (e.g. monoclonal antibodies within 30 days of the start (Day 1) of study treatment, except for BTKi for participants included in cohort B, that can be pursued until C1D1 and except for topical treatment or hormone treatment if criterion 33 is respected. treatment ≤1 mg/kg/day prednisone or equivalent is allowed within 2 weeks prior to Obinutuzumab infusion.
  6. \< 50% as determined by echocardiography or isotopic method.
  7. cardiovascular disease such as uncontrolled, unstable or symptomatic arrhythmias, unstable angina, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class III (moderate) or Class IV (severe) cardiac disease as defined by the Functional Classification or Objective Assessment Class C or D cardiac disease. Heart rate- interval > 480 milliseconds based on Fridericia's formula.; History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place; Uncontrolled hypertension as indicated by a minimum of 2 consecutive blood pressure measurements, at screening, showing systolic blood pressure > 170 mmHg and diastolic blood pressure > 105 mmHg and/or uncontrolled hypertension with systolic blood pressure>140mmHg despite a well conduct hypertensive treatment for at least 6 months
  8. level \< 8g/dL; Absolute Neutrophil count \<1 G/L (\<0,5G/L if related to lymphoma); Platelets \< 75 G/L (\< 50 G/L if related to lymphoma),
  9. Major surgery within 28 days before screening.
  10. Require the use of anticoagulation by warfarin or equivalent vitamin K antagonists (e.g., phenprocoumone)
  11. Requires treatment with a moderate or a strong inhibitor or inducer.
  12. Vaccinated with live, attenuated vaccines within 4 weeks of enrollment (except COVID vaccine) or anticipation that such a will be required during the study.
  13. Known to active substances or to any of the . Or to any study treatments.
  14. Known allergy to all xanthine oxidase inhibitors or rasburicase.
  15. Previously documented G6DP deficiency.
  16. Severe prior reactions to anti CD20 monoclonal antibodies or prior significant toxicity (other than thrombocytopenia) with Bcl-2 inhibitor.
  17. Prior treatment with systemic medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents), within 2 weeks or five half-lives (whichever is shorter) prior to first dose of study treatment.
  18. Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
  19. History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention.
  20. Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, neurodegenerative disease: or intracranial hemorrhage: Participants with a history of stroke or intracranial hemorrhage who have not experienced a stroke or or intracranial hemorrhage within the past 2 years and have no residual neurologic deficits, as judged by the investigator, are allowed.
  21. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection (as evaluated by the investigator) within 4 weeks prior to the first study treatment.
  22. Known (HIV), for participants with unknown HIV status, HIV testing will be performed at screening if required by local regulations.
  23. Positive test results for virus (HCV) antibody: Participants who are positive for HCV antibody are eligible only if PCR is negative for HCV RNA.
  24. Positive test results for virus (HBV) infection (defined as positive HbsAg serology) Participants with occult or prior HBV infection (defined as negative HbsAg and positive HbcAb) may be included if HBV DNA is undetectable, provided that they are willing to undergo DNA testing on Day 1 of every cycle and every three months for at least 12 months after the last cycle of study treatment and appropriate antiviral therapy.
  25. Positive SARS-CoV-2 test within 7 days prior to enrollment. Rapid antigen test result is also acceptable.
  26. Documented SARS-CoV-2 infection within 6 months of first study treatment (Cycle 1 Day 1): Participants may be eligible if they have no persistent respiratory symptoms, no evidence of lung infiltrates on chest CT, and have a negative PCR during the first 30 days prior to first study treatment (Cycle 1 Day 1)
  27. Suspected or latent tuberculosis (confirmed by positive interferon-γ release assay)
  28. Known or suspected chronic active Epstein-Barr viral infection.
  29. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator opinion, could compromise the participant's safety, interfere with the absorption or metabolism of study treatments, or put the study outcomes at undue risk.
  30. Prior allogenic SCT is allowed if no active and no active immune-suppressive treatment (to be discussed with the medical monitor).
  31. Active disease requiring treatment:

    1. Participants with a history of autoimmune-related hypothyroidism on a stable dose of thyroid-replacement hormone may be eligible.
    2. Participants with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
    3. Participants with a history of autoimmune hepatitis, systemic lupus erythematosus, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener granulomatosis, Sjögren syndrome, multiple sclerosis, or glomerulonephritis will be excluded.
    4. Participants with a history of immune thrombocytopenic purpura, autoimmune hemolytic anaemia, Guillain-Barré syndrome, myasthenia gravis, myositis rheumatoid arthritis, vasculitis, or other autoimmune diseases will be excluded unless they have not required systemic therapy in the last 12 months.
  32. Participant with history of confirmed progressive multifocal leukoencephalopathy (PML)
  33. Active other than the one treated in this research. Prior history of malignancies unless the participant has been free of the disease for ≥ 2 years. However, participants with the following history/concurrent conditions are allowed:

    1. Basal or squamous cell carcinoma of the skin
    2. Carcinoma in situ of the cervix
    3. Carcinoma in situ of the breast
    4. Incidental histologic finding of prostate cancer (T1a or T1b) using the tumor, nodes, [TNM] clinical staging system.
  34. Pregnant, planning to become pregnant or lactating WOCBP.
  35. Any significant medical conditions, laboratory abnormality or psychiatric illness likely to interfere with participation or understanding of study requirements (according to the investigator's decision).
  36. Severe or debilitating pulmonary disease, history of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases, including but not limited to pulmonary fibrosis and acute lung diseases.
  37. Known or suspected history of HLH unless related to lymphoma.
  38. Clinically significant history of cirrhotic liver disease, ongoing, drug-induced liver injury, alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, ongoing extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension.
  39. or PT > 1.5 x ULN, or Quick percentage \< 70% (if Quick percentage used in lieu of time-based units for reporting PT), in the absence of therapeutic anticoagulation.
  40. aPTT >1.5 x ULN in the absence of therapeutic anticoagulation or a lupus anticoagulant.
  41. Prior solid organ transplantation.
  42. Person deprived of his/her liberty by a judicial or administrative decision.
  43. Person hospitalized without consent.
  44. Adult person under legal protection.

NB: for 42, 43, 44 if there is an individual benefit for such participants, an Ethics Committee will have to be informed case by case.

Terms in these criteria, in plain language(38)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Cohort A - POD24

    * Obinutuzumab IV infusion 2000 mg flat dose at C1D1 or Splited in 2 doses of 1000 mg at C1D1 and C1D2 * Glofitamab IV infusion 2.5 mg C1D8 10 mg C1D15 30 mg C2D1 and C3D1 (infusion during min 4 hours ) 30 mg Each D1 for C4 to C6 (Infusion during min 2 hours ) 30 mg Each D1 for C7 to C12 (Infusion during min 90 min) * Zanubrutinib PO 320 mg total daily dose (QD) From C1D2 continuously until end C35 * Venetoclax PO 20 mg/d C2D3 to C2D7 50 mg/d C2D8 to C2D14 100 mg/d C2D15 to C2D21 200 mg/d C3D1 to C3D7 400 mg/d From C3D8 continuously until end C35

    Drug: Obinutuzumab · Drug: Glofitamab · Drug: Venetoclax Oral Product

  • Experimental
    Cohort B - BTKI failure

    * Obinutuzumab IV infusion 2000 mg flat dose at C1D1 or Splited in 2 doses of 1000 mg at C1D1 and C1D2 * Glofitamab IV infusion 2.5 mg C1D8 10 mg C1D15 30 mg C2D1 and C3D1 (infusion during min 4 hours ) 30 mg Each D1 for C4 to C6 (Infusion during min 2 hours ) 30 mg Each D1 for C7 to C12 (Infusion during min 90 min) * Venetoclax PO 20 mg/d C2D3 to C2D7 50 mg/d C2D8 to C2D14 100 mg/d C2D15 to C2D21 200 mg/d C3D1 to C3D7 400 mg/d From C3D8 continuously until end C35

    Drug: Obinutuzumab · Drug: Glofitamab · Drug: Venetoclax Oral Product

  • Experimental
    Cohort C - first Line

    * Obinutuzumab IV infusion 2000 mg flat dose at C1D1 or Splited in 2 doses of 1000 mg at C1D1 and C1D2 * Glofitamab IV infusion 2.5 mg C1D8 10 mg C1D15 30 mg C2D1 and C3D1 (infusion during min 4 hours ) 30 mg Each D1 for C4 to C6 (Infusion during min 2 hours ) 30 mg Each D1 for C7 to C12 (Infusion during min 90 min) * Zanubrutinib PO 320 mg total daily dose (QD) From C1D2 continuously until end C35 * Venetoclax PO 20 mg/d C2D3 to C2D7 50 mg/d C2D8 to C2D14 100 mg/d C2D15 to C2D21 200 mg/d C3D1 to C3D7 400 mg/d From C3D8 continuously until end C35

    Drug: Obinutuzumab · Drug: Glofitamab · Drug: Venetoclax Oral Product · Drug: Zanubrutinib Oral Capsule

Interventions

06

What researchers measure

Primary outcomes

  1. PFS at the end of C17 (each cycle is 21 days)

    The primary efficacy endpoint is the PFS at 12 months (end of C17) from first dose of study treatment, in each cohort: Zanubrutinib/Venetoclax/Glofitamab for cohorts A and C, Venetoclax/Glofitamab for cohort B, as determined by imaging central review (Lugano 2014 criteria),

    Time frame: end of cycle 17 (each cycle is 21 days)

Secondary outcomes

  1. Overall Response Rate (ORR) and Complete Response Rate (CRR)

    ORR and CRR as determined by PET-CT evaluation according to Lugano 2014 (imaging central review and local assessment) and at end of C35 (24 months) determined by CT-scan only

    Time frame: End of C3 (each cycle is 21 days), end of C6 (each cycle is 21 days), end of C12 (each cycle is 21 days), end of C17 (each cycle is 21 days), end of C26 (each cycle is 21 days))

  2. PFS at the end of C17 as determined by investigator

    PFS at 12 months (end of C17) from first dose of study treatment as determined by investigator (Lugano 2014 criteria

    Time frame: end of cycle 17 (each cycle is 21 days)

  3. Duration of response (DOR)

    Duration of response (DOR) as determined by investigator (Lugano 2014 criteria) defined as time from first documented Complete Response or Partial Response to date of disease progression or death,

    Time frame: 72 months

  4. Event-free survival (EFS)

    Event-free survival (EFS) as determined by investigator (Lugano 2014 criteria) defined as time from first dose of study treatment to earliest of: progression, next anti-lymphoma treatment, or death.

    Time frame: 74 months

  5. Disease Free Survival (DFS)

    Disease Free Survival (DFS) as determined by investigator (Lugano 2014 criteria) defined as time from first dose of study treatment to earliest of: progression, or death from lymphoma.

    Time frame: 74 months

  6. Overall Survival (OS)

    Overall survival defined as time from first dose of study treatment to death from any cause,

    Time frame: 74 months or death

  7. Time to next anti-lymphoma treatment (TTNT)

    Time to next anti-lymphoma treatment (TTNT) defined as time from first dose of study treatment to earliest date of next anti-lymphoma treatment (except corticosteroids)

    Time frame: date of next anti-lymphoma treatment (74 months)

  8. Safety and tolerability:

    Incidence of grade ≥3 adverse events, adverse events of special interest (AESI).

    Time frame: from ICF signature until 28 days after the last treatment administration

  9. Minimal Residual Disease (MRD)

    MRD response

    Time frame: before Cycle 1 Day1 (baseline), end of C3 (each cycle is 21 days), end of C6 (each cycle is 21 days), end of C17 (each cycle is 21 days)

07

Study locations

16 of 16 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for May 2028, 39 months after the start.

Of 154 non-industry phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 108. This study's planned 39 months is below that.

Counting every sponsor, half of 184 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
Aug 16, 2024
StartActual
Feb 21, 2025
Primary completionEst.
May 2028
CompletionEst.
Mar 2032
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06558604
Lead sponsor
The Lymphoma Academic Research Organisation
Responsible party
Sponsor
First posted
Aug 16, 2024
Start date
Feb 21, 2025
Primary completion
May 2028 (estimated)
Completion
Mar 2032 (estimated)
Last update
Jul 10, 2026

Study contacts

Julie JULIE ASSEMAT
Contact
julie.assemat@lysarc.org
+33 (4) 27 01 27 51
Steven LE GOUILL, Pr
study chair · Institut Curie
Clementine SARKOZY, MD
study chair · Institut Curie
Louise ROULIN, MD
study chair · Hôpital Henri-Mondor - AP-HP
Gilles CROCHET, MD
study chair · CHU Dinant Godinne UCL Namur - YVOIR

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glofitamab · Venetoclax

Start the discussion